
    
      The primary objective of this study will be to compare paliperidone palmitate treatment with
      the randomly assigned oral antipsychotic treatment in delaying time to treatment failure over
      12 months in subjects diagnosed with schizophrenia who were recently discharged from an
      inpatient psychiatric hospital. Patients will receive either paliperidone palmitate 78, 117,
      156, or 234 mg monthly by injection for twelve months OR oral aripiprazole, haloperidol,
      olanzapine, paliperidone, perphenazine, quetiapine, and risperidone at doses selected by the
      study doctor.
    
  